The Edmond J. Safra Program for Parkinson Disease, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.
The Ken and Ruth Davee Neurology Department, Northwestern University, 303 E Chicago avenue, Ward 12th floor, Chicago, IL, 60611, USA.
J Neural Transm (Vienna). 2021 Apr;128(4):483-498. doi: 10.1007/s00702-020-02290-z. Epub 2021 Jan 1.
Dystonia is a clinically, genetically, and biologically heterogeneous hyperkinetic movement disorder caused by the dysfunctional activity of neural circuits involved in motor control. Our understanding of the molecular mechanisms underlying dystonia pathogenesis has tremendously grown thanks to the accelerated discovery of genes associated with monogenic dystonias (DYT-genes). Genetic discoveries, together with the development of a growing number of cellular and animal models of genetic defects responsible for dystonia, are allowing the identification of several areas of functional convergence among the protein products of multiple DYT-genes. Furthermore, unexpected functional links are being discovered in the downstream pathogenic molecular mechanisms of DYT-genes that were thought to be unrelated based on their primary molecular functions. Examples of these advances are the recognition that multiple DYT-genes are involved in (1) endoplasmic reticulum function and regulation of the integrated stress response (ISR) through Eukaryotic initiation factor 2 alpha signaling; (2) gene transcription modulation during neurodevelopment; (3) pre-and post-synaptic nigrostriatal dopaminergic signaling; and (4) presynaptic neurotransmitter vesicle release. More recently, genetic defects in the endo-lysosomal and autophagy pathways have also been implicated in the molecular pathophysiology of dystonia, suggesting the existence of mechanistic overlap with other movement disorders, such as Parkinson's disease. Importantly, the recognition that multiple DYT-genes coalesce in shared biological pathways is a crucial advance in our understanding of dystonias and will aid in the development of more effective therapeutic strategies by targeting these convergent molecular pathways.
肌张力障碍是一种临床、遗传和生物学上表现多样的运动障碍,由涉及运动控制的神经回路功能障碍引起。由于与单基因肌张力障碍(DYT 基因)相关的基因的加速发现,我们对肌张力障碍发病机制的分子机制的理解有了极大的提高。遗传发现,以及越来越多的负责肌张力障碍的遗传缺陷的细胞和动物模型的发展,使我们能够确定多个 DYT 基因的蛋白产物之间的几个功能汇聚区。此外,在 DYT 基因的下游致病分子机制中,人们发现了意想不到的功能联系,这些联系以前被认为是基于它们的主要分子功能而无关的。这些进展的例子包括认识到多个 DYT 基因参与了(1)内质网功能和通过真核起始因子 2α信号调节整体应激反应(ISR);(2)神经发育过程中的基因转录调节;(3)黑质纹状体多巴胺能前突触和后突触信号传递;(4)前突触神经递质囊泡释放。最近,内体溶酶体和自噬途径的遗传缺陷也与肌张力障碍的分子病理生理学有关,这表明与其他运动障碍(如帕金森病)存在机制重叠。重要的是,认识到多个 DYT 基因在共同的生物学途径中聚集,是我们对肌张力障碍理解的一个重要进展,通过靶向这些收敛的分子途径,将有助于开发更有效的治疗策略。